News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AbbVie (ABBV)'s Battle For Shire: Why This Time It's Different



7/7/2014 6:43:49 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Just five weeks after Pfizer walked away from its £70bn attempt to buy AstraZeneca, another American suitor has come knocking on the door of a London-listed pharmaceutical company, lured by the tantalising prospect of the much lower tax rate that comes with a European domicile.

On the face of it, AbbVie’s $46bn (£27bn) pursuit of Shire looks to have more than just the brushstrokes of Pfizer and AstraZeneca – a US drugmaker, eyeing a UK target, with tax advantages at the forefront of rationale.

But the latest deal has failed to provoke the political furore that Pfizer’s bid for AstraZeneca ignited.

Help employers find you! Check out all the jobs and post your resume.

Read at Telegraph


comments powered by Disqus
Telegraph
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES